{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALS&page=31",
    "query": {
      "condition": "ALS",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 487,
    "total_pages": 49,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALS&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALS&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T12:41:22.553Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00339976",
      "title": "Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "ALS"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Environmental Health Sciences (NIEHS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2002-08-06",
      "completion_date": "2008-04-21",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Research Triangle Park, North Carolina",
      "locations": [
        {
          "city": "Research Triangle Park",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00339976"
    },
    {
      "nct_id": "NCT03645031",
      "title": "Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Neuromuscular Diseases"
      ],
      "interventions": [
        {
          "name": "Acute Intermittent Hypoxia",
          "type": "OTHER"
        },
        {
          "name": "Sham Acute Intermittent Hypoxia",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2018-10-01",
      "completion_date": "2023-06-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03645031"
    },
    {
      "nct_id": "NCT05039099",
      "title": "A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AL-S Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2021-09-02",
      "completion_date": "2025-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039099"
    },
    {
      "nct_id": "NCT02118805",
      "title": "Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Myasthenia Gravis",
        "Myopathies",
        "Stroke",
        "Parkinson's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "20 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2013-10",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02118805"
    },
    {
      "nct_id": "NCT05797753",
      "title": "A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "SAR443820",
          "type": "DRUG"
        },
        {
          "name": "Erythromycin ethyl succinate",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2022-02-18",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797753"
    },
    {
      "nct_id": "NCT03868345",
      "title": "Speech Analysis in ALS Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ALS",
        "Amyotrophic Lateral Sclerosis",
        "Lou Gehrig Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Barrow Neurological Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-02-18",
      "completion_date": "2021-04-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868345"
    },
    {
      "nct_id": "NCT00076154",
      "title": "National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ALS"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2121,
      "start_date": "2003-01",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076154"
    },
    {
      "nct_id": "NCT07423494",
      "title": "Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "nL-CHCHD-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "n-Lorem Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2026-03",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07423494"
    },
    {
      "nct_id": "NCT03472950",
      "title": "Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALS"
      ],
      "interventions": [
        {
          "name": "Ranolazine 500 MG",
          "type": "DRUG"
        },
        {
          "name": "Ranolazine 1000 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-06-11",
      "completion_date": "2022-12-09",
      "has_results": true,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472950"
    },
    {
      "nct_id": "NCT03456882",
      "title": "The Effect of RNS60 on ALS Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "RNS60",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mario Negri Institute for Pharmacological Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 147,
      "start_date": "2017-05-30",
      "completion_date": "2021-05-30",
      "has_results": true,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-10-22T12:41:22.553Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03456882"
    }
  ]
}